Avalon GloboCare granted Hong Kong patent for CAR-T/CAR-NK cell technology

Avalon GloboCare Corp.

Hong Kong Intellectual Property Department issued standard patent HK40074322 for CAR-T and CAR-NK cell technology.
Patent term of 20 years effective February 21, 2020, providing protection through 2040 in Hong Kong.
Co-developed with strategic partner Arbele Limited; complements existing US and PCT patent protections.
Technology features bispecific Anti-CD19xCD22 CAR design and localized cytokine induction to enhance efficacy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.